Form 4 for AMGN Amgen

Accepted 2021-11-03 00:00:00 ET · period of report 2021-11-01 · accession 0001127602-21-028365 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2021-11-03	2021-11-01	AMGN	Johnston Lori A	EVP, HR	F - Tax	$206.97	-1,352	36.3K	-4%	-$279.8K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-11-01	F	D	1,352	$206.97	36,269	D	—	—	(F1) These shares include the following RSUs granted under the Company's equity plans: 690 RSUs which will vest on 4/27/2022; 1,361 RSUs which will vest in installments of 670 on 5/3/2022 and 691 on 5/3/2023; 5,226 RSUs which will vest in installments of 2,574 on 11/1/2022 and 2,652 on 11/1/2023; 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024; and 3,296 RSUs which vest in installments of 1,087 on 4/30/2023, 1,088 on 04/30/2024 and 1,121 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. (F2) These shares include 668 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.